Correlation Between Pathological and MRI Radiological Tumor Responses to Neoadjuvant Chemotherapy in Non-Luminal Breast Cancer: A Single Institution Experience

IF 1.5 Q4 ONCOLOGY
Cancer reports Pub Date : 2025-07-13 DOI:10.1002/cnr2.70275
Wesal M. Eldehna, Fawzy Elbarbry, Abdul Hameed Hassan, Rafat Abu Shakra, Ahmed Elaryan, Ola Mousa Abdelfattah Elnady, Elshaimaa Mohamed Mohamed
{"title":"Correlation Between Pathological and MRI Radiological Tumor Responses to Neoadjuvant Chemotherapy in Non-Luminal Breast Cancer: A Single Institution Experience","authors":"Wesal M. Eldehna,&nbsp;Fawzy Elbarbry,&nbsp;Abdul Hameed Hassan,&nbsp;Rafat Abu Shakra,&nbsp;Ahmed Elaryan,&nbsp;Ola Mousa Abdelfattah Elnady,&nbsp;Elshaimaa Mohamed Mohamed","doi":"10.1002/cnr2.70275","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Neoadjuvant chemotherapy (NACT) is the standard treatment for patients with locally advanced breast cancer. In recent years, it has also been used for early-stage triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2-positive (HER2<sup>+</sup>) breast cancers.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Our hypothesis asserts a correlation between breast radiological and pathological response post-NACT in non-luminal breast cancer patients. We also aimed to determine the predictive value of MRI in predicting response in these patients. Radiologist agreement upon radiological MRI response is also highlighted in the current study.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective study to evaluate MRI's accuracy for assessing tumor response to NACT in early and locally advanced non-metastatic breast cancer patients in comparison with pathological assessments. We enrolled cases that were treated with neoadjuvant chemotherapy between December 2019 and November 2023.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Dynamic MRI's sensitivity to detect tumor response is 86.4%, its specificity is 96.8%, and its accuracy is 92.4%, with a significant <i>p</i>-value. So, the high correlation between measurements of residual disease detected by MRI and those detected by pathological assessment supports the use of MRI for imaging assessment during NACT. The two radiologists involved in our study were in good agreement in their assessment of radiological response (Kappa: 0.801, sensitivity: 85.7%, specificity: 93.8%, and accuracy: 90.6%).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The accuracy of imaging assessment by breast MRI during NACT is validated by the greater correlation between measurements of residual disease on MRI and pathology, establishing its role as the most precise imaging modality. We strongly advocate for the dependable role of MRI in monitoring breast lesions during neoadjuvant therapy, especially in non-luminal breast cancer cases, regardless of whether they present as mass or non-mass enhancement patterns.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 7","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70275","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70275","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Neoadjuvant chemotherapy (NACT) is the standard treatment for patients with locally advanced breast cancer. In recent years, it has also been used for early-stage triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2-positive (HER2+) breast cancers.

Objectives

Our hypothesis asserts a correlation between breast radiological and pathological response post-NACT in non-luminal breast cancer patients. We also aimed to determine the predictive value of MRI in predicting response in these patients. Radiologist agreement upon radiological MRI response is also highlighted in the current study.

Methods

A retrospective study to evaluate MRI's accuracy for assessing tumor response to NACT in early and locally advanced non-metastatic breast cancer patients in comparison with pathological assessments. We enrolled cases that were treated with neoadjuvant chemotherapy between December 2019 and November 2023.

Results

Dynamic MRI's sensitivity to detect tumor response is 86.4%, its specificity is 96.8%, and its accuracy is 92.4%, with a significant p-value. So, the high correlation between measurements of residual disease detected by MRI and those detected by pathological assessment supports the use of MRI for imaging assessment during NACT. The two radiologists involved in our study were in good agreement in their assessment of radiological response (Kappa: 0.801, sensitivity: 85.7%, specificity: 93.8%, and accuracy: 90.6%).

Conclusions

The accuracy of imaging assessment by breast MRI during NACT is validated by the greater correlation between measurements of residual disease on MRI and pathology, establishing its role as the most precise imaging modality. We strongly advocate for the dependable role of MRI in monitoring breast lesions during neoadjuvant therapy, especially in non-luminal breast cancer cases, regardless of whether they present as mass or non-mass enhancement patterns.

Abstract Image

非腔内乳腺癌对新辅助化疗的病理和MRI放射学肿瘤反应的相关性:单一机构经验
背景新辅助化疗(NACT)是局部晚期乳腺癌患者的标准治疗方法。近年来,它也被用于早期三阴性乳腺癌(TNBC)和人表皮生长因子受体2阳性(HER2+)乳腺癌。目的:我们的假设证实了非腔内乳腺癌患者nact后乳房放射学和病理反应之间的相关性。我们还旨在确定MRI在预测这些患者反应方面的预测价值。放射科医生对放射MRI反应的一致意见也在当前的研究中得到强调。方法回顾性研究MRI对早期和局部晚期非转移性乳腺癌患者NACT疗效评估的准确性,并与病理评估进行比较。我们纳入了2019年12月至2023年11月期间接受新辅助化疗的病例。结果动态MRI检测肿瘤反应的敏感性为86.4%,特异性为96.8%,准确率为92.4%,p值显著。因此,MRI检测到的残留疾病测量值与病理评估检测到的残留疾病测量值之间的高度相关性支持在NACT期间使用MRI进行成像评估。参与我们研究的两名放射科医生对放射反应的评估非常一致(Kappa: 0.801,敏感性:85.7%,特异性:93.8%,准确性:90.6%)。结论在NACT期间,乳腺MRI成像评估的准确性得到了验证,MRI残留病变的测量与病理之间存在较大的相关性,确立了其作为最精确的成像方式的地位。我们强烈提倡MRI在新辅助治疗期间监测乳腺病变的可靠作用,特别是在非腔内乳腺癌病例中,无论它们是肿块还是非肿块增强模式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer reports
Cancer reports Medicine-Oncology
CiteScore
2.70
自引率
5.90%
发文量
160
审稿时长
17 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信